Medikamentöse Therapie von kognitiven und Verhaltensstörungen bei Demenz

Aufgrund der demografischen Entwicklung wird die Anzahl von an Demenz Erkrankten künftig weiter zunehmen. Allgemeinmediziner, Geriater, Neurologen und Psychiater sollten wissen, wie kognitive und Verhaltensauffälligkeiten von Demenzkranken behandelt werden können. Dieser an den aktuellen S3-Leitlinien Demenzen orientierte Artikel gibt einen Überblick der derzeitigen medikamentösen Therapieoptionen bei den häufigsten Demenzerkrankungen.

Schlüsselwörter

Alzheimer-Krankheit - Lewy-Körper-Erkrankung - Delir - Acetylcholinesterase-Hemmer - Apathie

• Literatur

• 1 Alzheimer Europe, EuroCoDe. Prevalence of dementia in Europe. Im Internet: http://www.alzheimer-europe.org/Research/European-Collaboration-on-Dementia/Prevalence-of-dementia/Prevalence-of-dementia-in-Europe Stand: 19.04.2018
• 2 Langa KM, Larson EB, Crimmins EM. et al. A comparison of the prevalence of dementia in the United States in 2000 and 2012. JAMA Intern Med 2017; 177: 51-58
• 3 Ahmadi-Abhari S, Guzman-Castillo M, Bandosz P. et al. Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040: modelling study. Br Med J 2017; 358: j2856
• 4 Qiu C, De Ronchi D, Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry 2007; 20: 380-385
• 5 Jellinger KA, Attems J. Neuropathological evaluation of mixed dementia. J Neurol Sci 2007; 257: 80-87
• 6 McKeith I, Taylor JP, Thomas A. et al. Revisiting DLB diagnosis: A consideration of prodromal DLB and of the diagnostic overlap with Alzheimer disease. J Geriatric Psychiatry Neurol 2016; 29: 249-253
• 7 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Hrsg. Cholinesterasehemmer bei Alzheimer Demenz. Abschlussbericht A05-19A (Version 1.0, Stand: 7.2.2007). Köln: IQWiG; 2007
• 8 Howard R, McShane R, Lindesay J. et al. Donepezil and memantine for moderate-to-severe Alzheimerʼs disease. N Engl J Med 2012; 366: 893-903
• 9 Winblad B, Kilander L, Eriksson S. et al. Donepezil in patients with severe Alzheimerʼs disease: doubleblind, parallel-group, placebo-controlled study. Lancet 2006; 367: 1057-1065
• 10 Winblad B, Jones RW, Wirth Y. et al. Memantine in moderate to severe Alzheimerʼs disease: a metaanalysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007; 24: 20-27
• 11 Veronese N, Stubbs B, Maggi S. et al. Low-dose aspirin use and cognitive function in older age: A systematic review and meta-analysis. J Am Geriatr Soc 2017; 65: 1763-1768
• 12 Vann Jones SA, OʼBrien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med 2014; 44: 673-683
• 13 McKeith IG, Boeve BF, Dickson DW. et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017; 89: 88-100
• 14 Perry EK, Haroutunian V, Davis KL. et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimerʼs disease. Neuroreport 1994; 5: 747-749
• 15 Matsunaga S, Kishi T, Yasue I. et al. Cholinesterase inhibitors for Lewy Body disorders: A meta-analysis. Int J Neuropsychopharmacol 2015; 19: 1-15
• 16 Stinton C, McKeith I, Taylor JP. et al. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry 2015; 172: 731-742
• 17 Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinsonʼs disease dementia. Cochrane Database Syst Rev 2006; (01) CD004747
• 18 Grossman M. The non-fluent/agrammatic variant of primary progressive aphasia. Lancet Neurol 2012; 11: 545-555
• 19 Tariot PN, Erb R, Podgorski CA. et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155: 54-61
• 20 Sultzer DL, Davis SM, Tariot PN. et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimerʼs disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008; 165: 844-854